To understand how Medical Cannabis works in the body as a mast cell stabilizer we must first understand how our Endocannabinoid system works.
What is the Endocannabinoid system (ECS)?
The endocannabinoid system (ECS) refers to a collection of cell receptors and corresponding molecules. You can think of cell receptors like little locks on the surface of your cells. The keys to these locks are chemical molecules called agonists. Each time an agonist binds to a cell it relays a message, causing a cascade of chemical effects.
The endocannabinoid system is the name for a series of cell receptors that respond to certain kinds of agonists. Two primary cell receptors make up the ECS, Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2). The keys to these receptors are called endocannabinoids.
Endocannabinoids are like the body’s natural THC.
The cannabinoid receptors are found on the surface of the cells. Think of these receptors like a keyhole that will only function if the right key is inserted into it.
There are many types of cannabinoid receptors but only two of them have been widely studied and researched. They are CB1 and CB2.
Each receptor responds to different kinds of cannabinoids, but there are some cannabinoids that don’t distinguish between the two and can interact with both.
The distribution of these receptors within the body system explains why cannabinoids have certain profound effects on us.
CB1 receptors are abundantly present in the brain and spinal cord. They are found in exceedingly high concentration in the parts of the brain that are associated with the behaviors they influence.
Most importantly, they are found in the hypothalamus and the amygdala, which are responsible for appetite regulation, control of stress and anxiety, reducing nausea as well as for memory and emotional processing.
CB1 receptors are also present in nerve endings where they act to reduce sensations of pain (one major reason why cannabis is used as a pain killer).
CB2 receptors are usually located in the immune cells of the peripheral nervous system. Once activated, they trigger an immune response to reduce inflammation, a role that is important in treating many chronic diseases.
“The presence of CB2 (and CB1) in immune system cells strongly suggests that endocannabinoids are immunomodulators.”- Differential Roles of CB1 and CB2 Cannabinoid Receptors in Mast Cells
Research shows that cannabinoids can suppress mast cell degranulation.
“Cannabinoids are broadly immunosuppressive, and anti-inflammatory properties have been reported for certain marijuana constituents and endogenously produced cannabinoids. The CB2 cannabinoid receptor is an established constituent of immune system cells, and we have recently established that the CB1 cannabinoid receptor is expressed in mast cells. In the present study, we sought to define a role for CB1 in mast cells and to identify the signalling pathways that may mediate the suppressive effects of CB1 ligation on mast cell activation. Our results show that CB1 and CB2 mediate diametrically opposed effects on cAMP levels in mast cells. The observed long-term stimulation of cAMP levels by the Gαi/o-coupled CB1 is paradoxical, and our results indicate that it may be attributed to CB1-mediated transcriptional regulation of specific adenylate cyclase isoenzymes that exhibit superactivatable kinetics. Taken together, these results reveal the complexity in signalling of natively co-expressed cannabinoid receptors and suggest that some anti-inflammatory effects of CB1 ligands may be attributable to sustained cAMP elevation that, in turn, causes suppression of mast cell degranulation.“
A leading Mast Cell Activation Syndrome expert Dr. Afrin shares his experience with patients who use Medical Cannabis to help with their mast cell disease symptoms in his book Never Bet Against Occam.
“The mast cell surface features (inhibitory) cannabinoid receptors, making me wonder whether at least some of the chronically ill patients out there who claim that the only thing that makes them feel better is marijuana might be unrecognized MCAS patients in whom THC’s binding with the cannabinoid receptors on their dysfunctional mast cells leads to a quieting of the activity of those cells and thus a lessening of symptoms.“
*CBD alone without THC maybe ineffective at treating dysfunctional mast cells because THC has a strong binding affinity for both CB1 and CB2 receptors, cannabidiol (CBD) has no particular binding affinity. Instead, many of the therapeutic benefits of CBD are created through indirect actions.
In another research article,
“Cannabinomimetic Control of Mast Cell Mediator Release: New Perspective in Chronic Inflammation” published in the Journal of Neuroendocrinology provides detailed evidence backing up the fact that Medical Cannabis can suppress mast cell degranulation and help alleviate pain and inflammation in patients.
What Is the Best Way to Use Cannabis When You Have MCAS?
*Consult your doctor before making any change in your medical care. When trying Medical Cannabis remember that there are different strains of medical cannabis, one strain may give you great relief vs another may not.
If you’re considering using Medical Cannabis for Mast Cell Activation Syndrome you’re probably wondering how to take it. There are many Medical Cannabis treatment options available such as: Cannabis Edibles, Topical Ointments, Cannabis Oil, Smoking the Cannabis flower. However, when it comes to MCAS patients who are more severe, they tend to not tolerate ingesting the Medical Cannabis oil or edibles but may can inhale the actual Organic Medical Cannabis Flower and find great relief from MCAS symptoms.
“In the context of smoked marijuana, cannabinoids gain access to the systemic circulation within minutes of inhalation. However, airways and the gastrointestinal tract are immediate points of contact for cannabinoids constituents, and the resident mast cells in these areas will be impacted by marijuana smoke. Mast cells express CB2 cannabinoid receptors and a variety of responses to cannabinoid application have been described in these cells. In vitro, suppression of mast cell proinflammatory mediator release by both marijuana constituents and endocannabinoids has been described. The marijuana constituent tetrahydrocannabinol (THC) is highly suppressive in in vivo models of mast cell proinflammatory function.
It is recommended that MCAS patients only try organic medical cannabis as different pesticides and fertilizers can cause an allergic response. As with any medication there is a risk of an allergic reaction, so we encourage you to speak with your doctor.
Hemp Oil VS Medical Cannabis Oil
When trying Medical Cannabis Oil it is recommended to only use CBD/THC oils made strictly from medical marijuana for MCAS patients because of safety and superior medicinal benefits vs hemp.
CBD products made from hemp potentially have several problems:
• ” Industrial hemp typically contains far less cannabidiol than CBD-rich cannabis strains so a huge amount of industrial hemp is required to extract a small amount of CBD. This raises the risk of contaminants as hemp is a “bio-accumulator”—meaning the plant naturally drawns toxins from the soil.
• Hemp-derived CBD and refined CBD powder lack critical medicinal terpenes and secondary cannabinoids found in cannabis oil. These compounds interact with CBD and THC to enhance their medicinal benefits.” – The Travel Joint
MCAS patients want to make sure that the Medical Cannabis oil is CO2 derived as the other extraction process uses Ethanol (High-grade grain alcohol) and will likely cause anaphylaxis in Mast Cell Patients because Ethanol/Alcohol is known to cause mast cell degranalation.
Looking for a support group?
- Mast Cell & Tick-Borne Disease Awareness Group– (This group focuses on Mast Cell Activation Syndrome & Tick-Borne Disease, including Alpha-Gal Syndrome)
- Mast Cell Activation Syndrome Support (Mast Cell Activation Syndrome Only)
- Mast Movement (This group is open to Mastocytosis & Mast Cell Activation Syndrome)
Small-Howard AL, Shimoda LM, Adra CN, Turner H. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J. 2005;388(Pt 2):465-473. doi:10.1042/BJ20041682
De Filippis D, D’Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol. 2008 May;20 Suppl 1:20-5. doi: 10.1111/j.1365-2826.2008.01674.x. PMID: 18426495.
Differential Roles of CB1 and CB2 Cannabinoid Receptors in Mast CellsMaria-Teresa Samson, Andrea Small-Howard, Lori M. N. Shimoda, Murielle Koblan-Huberson, Alexander J. Stokes, Helen TurnerThe Journal of Immunology May 15, 2003, 170 (10) 4953-4962; DOI: 10.4049/jimmunol.170.10.4953
This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Ticked Off Mast Cells nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information of content on this site.